Results 141 to 150 of about 779,180 (303)

Characteristics linked to mortality risk among individuals with drug use disorders enrolled in drug rehabilitation facilities in Japan

open access: yesPCN Reports
Aim This study evaluated survival rates and examined characteristics associated with mortality among individuals with drug use disorder (DUD) enrolled in drug addiction rehabilitation facilities in Japan. Methods This longitudinal cohort study, conducted
Satomi Mizuno   +4 more
doaj   +1 more source

Dopamine D4 receptor counteracts morphine-induced changes in M opioid receptor signaling in the striosomes of the rat caudate putamen. [PDF]

open access: yes, 2015
Morphine is one of the most potent analgesic drugs used to relieve moderate to severe pain. After long-term use of morphine, neuroadaptive changes in the brain promotes tolerance, which result in a reduced sensitivity to most of its effects with ...
De-la-Calle-Martin, Adelaida   +6 more
core  

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

MicroRNA-132/212 negatively modulates opioid reward by targeting dopamine transporter in the ventral tegmental area

open access: yesTranslational Psychiatry
Addictive drugs, notably opioid drugs, have significant societal implications, yet the cellular and molecular mechanisms underpinning rewarding effects remain largely elusive.
Jie Meng   +12 more
doaj   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Diagnostic Reliability and Validity of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) Chinese Version. [PDF]

open access: yesComplex Psychiatry, 2021
Yang BZ   +10 more
europepmc   +1 more source

UNODC youth initiative: discussion guide. Draft. [PDF]

open access: yes, 2011
Contents: Section 1: Perceptions about Drug Use Section 2: What is Vulnerability? Section 3: The Direct Effects of Using Drugs Section 4: Abuse of Prescription Drug Section 5: Consequences and Risks Associated with Drug Use Section 6: Prevention ...

core  

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy